AltaValve Early Feasibility Study Protocol

NCT ID: NCT03997305

Last Updated: 2023-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-04

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Regurgitation Mitral Insufficiency Mitral Valve Incompetence Mitral Valve Regurgitation Mitral Incompetence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AltaValve

Transcatheter Mitral Valve Replacement

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects ≥ 18 years of age.
2. Subjects symptomatic New York Heart Association (NYHA) II-IV.
3. Subjects with severe MR as documented by echo.
4. Subjects who are at high risk for open-heart surgery as documented by the health care professional (e.g., Heart Team consisting of cardiac surgeon and interventional cardiologist in United States).

Exclusion Criteria

1. Inability to understand the study or a history of non-compliance with medical advice.
2. Unwilling or unable to sign the Informed Consent Form (ICF).
3. History of any cognitive or mental health status that would interfere with study participation.
4. Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.)).
5. Female subjects who are pregnant or planning to become pregnant within the study period.
6. Known hypersensitivity or contraindication to aspirin, heparin, or Warfarin without adequate alternative medications.
7. Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately medicated.
8. Known hypersensitivity to contrast media that cannot be adequately medicated.
9. Evidence of current Left Ventricular Ejection Fraction (LVEF) ≤30% (where current is defined as the latest LVEF measurement completed within 90 days prior to the index procedure).
10. Concurrent medical condition with a life expectancy of less than 12 months.
11. Prior mitral valve repair/replacement (excluding prior surgical mitral valve repair, annuloplasty, or MitraClip not interfering with AltaValve placement).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

4C Medical Technologies, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Genereux, MD

Role: PRINCIPAL_INVESTIGATOR

Morristown Medical Center

Vinayak Bapat, MD

Role: PRINCIPAL_INVESTIGATOR

Allina Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson Medical Center

Tucson, Arizona, United States

Site Status RECRUITING

Los Robles Regional Medical Center

Thousand Oaks, California, United States

Site Status RECRUITING

MedStar Washington Hospital

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Tampa General Hospital

Tampa, Florida, United States

Site Status RECRUITING

Emory University

Atlanta, Georgia, United States

Site Status RECRUITING

Cardiovascular Institute of the South

Houma, Louisiana, United States

Site Status RECRUITING

Morristown Medical Center

Morristown, New Jersey, United States

Site Status RECRUITING

Atrium Health

Charlotte, North Carolina, United States

Site Status RECRUITING

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, United States

Site Status RECRUITING

Baptist Memorial Hospital - Memphis

Memphis, Tennessee, United States

Site Status RECRUITING

Houston Methodist Hospital

Houston, Texas, United States

Site Status RECRUITING

Baylor Scott & White

Plano, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Adam Lawrence

Role: CONTACT

+1-727-318-2203

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ariana Ehsan, MD

Role: primary

520-324-5207

Mane Arabyan

Role: primary

805-796-3746

Erin C Collins, MPH

Role: primary

202-877-6622

Tatyana Harris

Role: primary

813-250-2392

Elizabeth Charles

Role: primary

404-686-1249

Jennifer Aucoin, LPN

Role: primary

Catherine VanZile

Role: primary

201-787-2254

Dana Amaro, RN

Role: primary

704-355-4692

Julie White

Role: primary

405-628-6865

Kari Fondren, RN

Role: primary

901-271-4062

Melissa Alanis, BSN, RN-BC

Role: primary

713-441-3629

Alexandra Finley

Role: primary

469-814-4235

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1890

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Alleviate-HF-1 Study
NCT04583527 COMPLETED PHASE1
Cephea Early Feasibility Study
NCT05061004 RECRUITING NA
ALLEVIATE-HF-HD Study
NCT05501652 COMPLETED PHASE1
INcrease Of VAgal TonE in CHF
NCT01303718 TERMINATED PHASE3